Remove Clinical Pharmacology Remove Compounding Remove Events
article thumbnail

From Healing to Harm: The Unintended Consequences of Polypharmacy in Seniors

PharmD Live

People over 65 make up only 14% of the population but account for 56% of hospitalizations for adverse drug events (ADEs) (Agency for Healthcare Research and Quality, AHRQ, 2021). The side effects can compound, resulting in a greater negative impact on a patient’s health than the individual effects of one medication alone.

article thumbnail

AdComms – Is FDA Getting Less Advice?

Eye on FDA

When Breakthrough Therapy (BT) designation is granted, then the drug gets Fast Track status and receives more intensive guidance – which can begin as early as Phase I clinical trials. That said, BT would be a lagging indicator since it can be granted so early in the development process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. Cannabis complications There are notable complexities to researching medical cannabis using a linear approach to clinical translation.

article thumbnail

2022 in review: Drug development milestones for tropical diseases

Pharmaceutical Technology

Pharmaceutical Technology lists some of the top events in the tropical disease arena in 2022. This year saw great progress towards making new therapeutics for malaria available sooner rather than later, says Karen Barnes, PhD, professor at the University of Cape Town’s Division of Clinical Pharmacology.